Creo Medical Group PLC (LON:CREO - Get Free Report) shares hit a new 52-week low during trading on Monday . The stock traded as low as GBX 18.61 ($0.24) and last traded at GBX 18.75 ($0.24), with a volume of 606412 shares trading hands. The stock had previously closed at GBX 19.50 ($0.25).
Creo Medical Group Stock Down 3.8 %
The company's 50 day simple moving average is GBX 24.99 and its 200-day simple moving average is GBX 30.36. The company has a current ratio of 3.24, a quick ratio of 2.19 and a debt-to-equity ratio of 29.96. The firm has a market cap of £67.83 million, a P/E ratio of -312.50 and a beta of 0.86.
Insider Activity at Creo Medical Group
In other Creo Medical Group news, insider Kevin Crofton acquired 2,916,666 shares of the stock in a transaction dated Monday, October 21st. The shares were purchased at an average price of GBX 24 ($0.31) per share, for a total transaction of £699,999.84 ($907,793.85). In related news, insider Kevin Crofton bought 2,916,666 shares of the firm's stock in a transaction that occurred on Monday, October 21st. The shares were bought at an average cost of GBX 24 ($0.31) per share, with a total value of £699,999.84 ($907,793.85). Also, insider Richard John Rees bought 98,000 shares of the stock in a transaction that occurred on Thursday, October 24th. The shares were bought at an average price of GBX 20 ($0.26) per share, for a total transaction of £19,600 ($25,418.23). 22.43% of the stock is owned by company insiders.
About Creo Medical Group
(
Get Free Report)
Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.
Further Reading
Before you consider Creo Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Creo Medical Group wasn't on the list.
While Creo Medical Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
